

Prof. Burak ŞAKAR

Personal Information

Office Phone: [+90 212 585 0007](tel:+902125850007)

Email: bsakar@istanbul.edu.tr

Web: <http://aves.istanbul.edu.tr/bsakar/>

Articles Published in Journals That Entered SCI, SSCI and AHCI Indexes

- I. **Temozolomide and capecitabine (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors.**
Dogan I., Tastekin D., Karabulut S., Sakar B.
JOURNAL OF CLINICAL ONCOLOGY, vol.39, no.3, 2021 (Journal Indexed in SCI)
- II. **Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy**
Aykan N. F. , Yildiz I., Sen F., Kilic L., Keskin S., Ciftci R., Karabulut S., Sakar B., Disci R.
MEDICAL ONCOLOGY, vol.30, no.3, 2013 (Journal Indexed in SCI)
- III. **Clinical outcome of rhabdomyosarcoma in adolescent and adult patients: Single center experience from Turkey**
Ustuner Z., Basaran M., Dizdar Y., Agaoglu F. Y. , Bilgic B., Sakar B., Basaran G. A. , Darendeliler E., Ozger H., Onat H., et al.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, vol.213, no.3, pp.221-229, 2007 (Journal Indexed in SCI)
- IV. **A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas**
Basaran M., Bavbek E. S. , Saglam S., Eralp L., Sakar B., Atalar A. C. , Bilgic B., Ozger H., Onat H.
ONCOLOGY, vol.72, pp.255-260, 2007 (Journal Indexed in SCI)
- V. **The prevalence and determinants of the use of complementary and alternative medicine in adult Turkish cancer patients.**
TAS F., USTUNER Z., CAN G., ERALP Y., CAMLICA H., BASARAN M., KARAGOL H., SAKAR B., Disci R., TOPUZ E.
Acta oncologica (Stockholm, Sweden), vol.44, no.2, pp.161-7, 2005 (Journal Indexed in SCI Expanded)
- VI. **Ewing's sarcoma of the axial system in patients older than 15 years: Dismal prognosis despite intensive multiagent chemotherapy and aggressive local treatment**
Argon A., Basaran M., Yaman F., Dizdar Y., Sakar B., Camlica H., Bavbek S. E. , Ozger H., Darendeliler E., Onat H.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, vol.34, no.11, pp.667-672, 2004 (Journal Indexed in SCI)
- VII. **Clinicopathologic factors influencing survival of patients with bile duct and gallbladder carcinoma**
Sakar B., Basaran M., Gumus M., Yazar A., Argon A., Aykan N. F.
ANNALS OF ONCOLOGY, vol.15, pp.243-244, 2004 (Journal Indexed in SCI)
- VIII. **Colorectal cancer in young patients: Characteristics and outcome**
Alici S., Aykan N., ŞAKAR B., Bulutlar G., Kaytan E., Topuz E.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, vol.199, no.2, pp.85-93, 2003 (Journal Indexed in SCI)
- IX. **A phase II study of paclitaxel and cisplatin combination chemotherapy in recurrent or metastatic head and neck cancer**
Başaran M., Bavbek S., Güllü İ., Demirelli F. H. , Şakar B., Tenekeci N., Altun M., Yalçın S., Onat H.
JOURNAL OF CHEMOTHERAPY, vol.14, pp.207-213, 2002 (Journal Indexed in SCI)
- X. **Hypertrophic osteoarthropathy associated with docetaxel treatment.**
Tas F., Aydinler A., Tenekeci N., Karadeniz A. N. , Sakar B., Topuz E.
Clinical oncology (Royal College of Radiologists (Great Britain)), vol.13, no.2, pp.145-6, 2001 (Journal Indexed in

Articles Published in Other Journals

- I. **A pilot study evaluating the safety and toxicity of epirubicin, cisplatin, and UFT (ECU regimen) in advanced gastric carcinoma**

Saglam S., Aykan N. F., ŞAKAR B., GÜLLÜOĞLU M., Balik E., Karanlık H.

JOURNAL OF GASTROINTESTINAL ONCOLOGY, vol.2, no.1, pp.19-26, 2011 (Journal Indexed in ESCI)

Refereed Congress / Symposium Publications in Proceedings

- I. **Do serum nectin-2 levels have a prognostic effect in patients with colorectal cancer?**

Basaran M., KARABULUT S., KARABULUT M., GUNALDI M., ALIS H., Erturk K., Vatansever S., Sakar B., Aykan N. F.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33

- II. **Prognostic roles of serum NEDD9 levels in patients with gastric cancer.**

Karabulut S., Karabulut M., Alis H., Bozbey H. U. , Sakar B., Vatansever S., Aykan N. F.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33

- III. **Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC)**

Keskin S., Sen F., AYDOGAN F., Ekenel M., Kilic L., SAGLAM S., Sakar B., Disci R., AYKAN F.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30

- IV. **Opere lokal ileri mide kanserli hastalarda adjuvan kemoterapi ile kemoradyoterapinin etkinliğinin karşılaştırılması**

ORDU C., KILIC L., EKENEL M., ŞAKAR B., AYKAN F.

III. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 24 - 28 March 2010, pp.121

- V. **Chemoradiotherapy in the adjuvant treatment of gastric cancer**

Saglam E. K. , Ozturk B., Baskaya S., Saglam S., Sakar B., Yamaner S., Balik E., Oral E. N. , Kizir A., Aykan F.

31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.315-316

Citations

Total Citations (WOS):136

h-index (WOS):6